IP Library Granted Patent US 8,283,328
Granted Patent B2
US 8,283,328 · App. 10/644,052 · Granted Oct 9, 2012

Immunostimulatory nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,283,328
App. No.
10/644,052
Granted
Oct 9, 2012
Kind
B2
Abstract

The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.

Claims (25)

1. An oligonucleotide having the following structure:

(SEQ ID NO: 313)

5′ T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*

T  3′,

wherein * refers to the presence of a phosphorothioate internucleotide linkage, and wherein _ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of 24-40 nucleotides.

2. The oligonucleotide of claim 1 , wherein the oligonucleotide consists essentially of 5′

(SEQ ID NO: 313)

5′ T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*

T 3′.

3. The oligonucleotide of claim 1 , wherein the oligonucleotide consists of

(SEQ ID NO: 313)

5′ T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*

T 3′.

4. An oligonucleotide having the following structure:

(SEQ ID NO: 313)

5′ T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T* 

T 3′

wherein each * refers to a phosphorothioate internucleotide linkage and each _ refers to a phosphodiester internucleotide linkage, and wherein the oligonucleotide is 24 nucleotides in length.

5. A pharmaceutical composition comprising an oligonucleotide as defined in claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising an oligonucleotide as defined in claim 4 and a pharmaceutically acceptable carrier.

7. An immunostimulatory oligonucleotide having at least two internal cytosine-guanine (CG) dinucleotides, wherein C is unmethylated cytidine, and G is guanosine, wherein the at least two internal CG dinucleotides have phosphodiester internucleotide linkages, wherein optionally each additional internal CG dinucleotide has a phosphodiester or stabilized internucleotide linkage, wherein all other internucleotide linkages are stabilized with a phosphorothioate internucleotide linkage, and wherein the immunostimulatory oligonucleotide is 6-100 nucleotides long.

8. The oligonucleotide of claim 7 , wherein the immunostimulatory oligonucleotide comprises a plurality of internal CG dinucleotides having a phosphodiester internucleotide linkage.

9. The oligonucleotide of claim 7 , wherein the immunostimulatory oligonucleotide is a B-Class immunostimulatory oligonucleotide.

10. The oligonucleotide of claim 7 , wherein the immunostimulatory oligonucleotide is not an antisense oligonucleotide, triple-helix-forming oligonucleotide, or ribozyme.

11. The oligonucleotide of claim 7 , wherein the oligonucleotide has a backbone comprising deoxyribose or ribose.

Assignments (3)
CONFIRMATION OF EXCLUSIVE PATENT LICENSE Recorded Dec 20, 2005
From: COLEY PHARMACEUTICAL GROUP, INC.; COLEY PHARMACEUTICAL GROUP, LTD.; COLEY PHARMACEUTICAL, GMBH
To: PFIZER INC.
Reel/Frame 017353/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2004
From: LIPFORD, GRAYSON; SAMULOWITZ, ULRIKE; VOLLMER, JORG; UHLMANN, EUGEN; JURK, MARION; RANKIN, ROBERT
To: COLEY PHARMACEUTICAL GMBH
Reel/Frame 014271/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2004
From: KRIEG, ARTHUR M.
To: COLEY PHARMAOEUTICAL GROUP, INC.
Reel/Frame 014271/0602 →